[
  {
    "sentence": "Focusing on diseases that may have been preceded by CHIP (58), we limited our investigation to studies that assessed patients by NGS at diagnosis of one of seven hematologic malignancies: acute lymphoid leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), MDS, and MPN (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Focusing on diseases that may have been preceded by CHIP (58), we limited our investigation to studies that assessed patients by NGS at diagnosis of one of seven hematologic malignancies: acute lymphoid leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), MDS, and MPN (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common hotspots were well-known and observed frequently even within individual studies (e.g., mutations at NRAS p.G12 were reported for 345 persons within 35 studies; Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Utilized transcripts are provided in Supplementary Table S1.Some of our identified mutation hotspots were unique to a specific hematologic malignancy (Fig. 2B; Supplementary Table S1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The most common hotspots were well-known and observed frequently even within individual studies (e.g., mutations at NRAS p.G12 were reported for 345 persons within 35 studies; Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some of our identified mutation hotspots were unique to a specific hematologic malignancy (Fig. 2B; Supplementary Table S1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This assessment found an additional 41 clonal mutations for this cohort (Supplementary Table S7) and found age to be associated with relaxed CHIP prevalence in this call set (OR, 1.025 per year of age; 95% CI, 1.004â€“1.048; P = 0.022; Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  }
]